This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ferrone, C. R. Articles by Warshaw, A. L. Search for Related Content PubMed PubMed Citation Articles by Ferrone, C. R. Articles by Warshaw, A. L. Social Bookmarking                            What's this?

Validation of a Postresection Pancreatic Adenocarcinoma Nomogram for Disease-Specific Survival

From the Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY; Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH; and Department of Surgery, Massachusetts General Hospital, Boston, MA.

Address reprint requests to Cristina R. Ferrone, MD, Memorial Sloan-Kettering Cancer Center, Department of Surgery, 1275 York Ave, Box 435, New York, NY 10021; e-mail: ferronec{at}mskcc.org

PURPOSE: Nomograms are statistically based tools that provide the overall probability of a specific outcome. They have shown better individual discrimination than the current TNM staging system in numerous patient tumor models. The pancreatic nomogram combines individual clinicopathologic and operative data to predict disease-specific survival at 1, 2, and 3 years from initial resection. A single US institution database was used to test the validity of the pancreatic adenocarcinoma nomogram established at Memorial Sloan-Kettering Cancer Center.

PATIENTS AND METHODS: The nomogram was created from a prospective pancreatic adenocarcinoma database that included 555 consecutive patients between October 1983 and April 2000. The nomogram was validated by an external patient cohort from a retrospective pancreatic adenocarcinoma database at Massachusetts General Hospital that included 424 consecutive patients between January 1985 and December 2003.

RESULTS: Of the 424 patients, 375 had all variables documented. At last follow-up, 99 patients were alive, with a median follow-up time of 27 months (range, 2 to 151 months). The 1-, 2-, and 3-year disease-specific survival rates were 68% (95% CI, 63% to 72%), 39% (95% CI, 34% to 44%), and 27% (95% CI, 23% to 32%), respectively. The nomogram concordance index was 0.62 compared with 0.59 with the American Joint Committee on Cancer (AJCC) stage (P = .004). This suggests that the nomogram discriminates disease-specific survival better than the AJCC staging system.

CONCLUSION: The pancreatic cancer nomogram provides more accurate survival predictions than the AJCC staging system when applied to an external patient cohort. The nomogram may aid in more accurately counseling patients and in better stratifying patients for clinical trials and molecular tumor analysis.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				C. R. Ferrone, D. A. Levine, L. H. Tang, P. J. Allen, W. Jarnagin, M. F. Brennan, K. Offit, and M. E. Robson BRCA Germline Mutations in Jewish Patients With Pancreatic Adenocarcinoma J. Clin. Oncol., January 20, 2009; 27(3): 433 - 438. [Abstract] [Full Text] [PDF]

				A. Iasonos, D. Schrag, G. V. Raj, and K. S. Panageas How To Build and Interpret a Nomogram for Cancer Prognosis J. Clin. Oncol., March 10, 2008; 26(8): 1364 - 1370. [Abstract] [Full Text] [PDF]

				J. S. Tomlinson, S. Jain, D. J. Bentrem, E. G. Sekeris, M. A. Maggard, O. J. Hines, H. A. Reber, and C. Y. Ko Accuracy of Staging Node-Negative Pancreas Cancer: A Potential Quality Measure Arch Surg, August 1, 2007; 142(8): 767 - 774. [Abstract] [Full Text] [PDF]